Novartis gains FDA approval for Afinitor® in advanced breast cancer marking a ... ITNews The approval was based on a randomized, double-blind, placebo-controlled, multi- center trial called BOLERO-2 (Breast cancer trials of OraL EveROlimus-2), which evaluated 724 postmenopausal women with advanced HR+ breast cancer with recurrence or ... |
